Viewpoints

EP. 1: Overview of diabetic eye disease

EP. 1: Overview of diabetic eye disease

EP. 2: Imaging for diabetic retinopathy

EP. 2: Imaging for diabetic retinopathy

EP. 3: Use of OCT-A for patients with diabetes

EP. 3: Use of OCT-A for patients with diabetes

EP. 4: Optimizing diabetes health management

EP. 4: Optimizing diabetes health management

EP. 5: Diabetes management: Communication between ODs and MDs

EP. 5: Diabetes management: Communication between ODs and MDs

EP. 6: Challenges to diabetes management

EP. 6: Challenges to diabetes management

EP. 7: ADA guidelines for DR/DME management

EP. 7: ADA guidelines for DR/DME management

EP. 8: Treatment options for DR/DME

EP. 8: Treatment options for DR/DME

EP. 9: Impact of COVID-19 on management of DR/DME

EP. 9: Impact of COVID-19 on management of DR/DME

EP. 10: Emerging agents for the treatment of DR/DME

EP. 10: Emerging agents for the treatment of DR/DME

EP. 1: Introduction and overview of dry eye

EP. 1: Introduction and overview of dry eye

EP. 2: Epidemiology and consequences of untreated dry eye

EP. 2: Epidemiology and consequences of untreated dry eye

EP. 3: Diagnosis and overlooking asymptomatic patients with dry eye

EP. 3: Diagnosis and overlooking asymptomatic patients with dry eye

EP. 4: Standard testing and assessment for dry eye disease

EP. 4: Standard testing and assessment for dry eye disease

EP. 5: General principles of treatment of dry eye disease

EP. 5: General principles of treatment of dry eye disease

EP. 6: Communication between ODs and MDs for optimal care

EP. 6: Communication between ODs and MDs for optimal care

EP. 7: Review of artificial tears for dry eye

EP. 7: Review of artificial tears for dry eye

EP. 8: Corticosteroids and Immunomodulators for the treatment of dry eye

EP. 8: Corticosteroids and Immunomodulators for the treatment of dry eye

EP. 9: The role of nutritional supplements and antibiotics in dry eye

EP. 9: The role of nutritional supplements and antibiotics in dry eye

EP. 10: Treating meibomian gland dysfunction

EP. 10: Treating meibomian gland dysfunction

EP. 11: In-office procedures and patient resistance for dry eye treatments

EP. 11: In-office procedures and patient resistance for dry eye treatments

EP. 12: Treatment methods for aqueous dry eye

EP. 12: Treatment methods for aqueous dry eye

EP. 13: Challenges in the management of dry eye

EP. 13: Challenges in the management of dry eye

EP. 14: Counseling and formulary concerns for dry eye therapies

EP. 14: Counseling and formulary concerns for dry eye therapies

EP. 15: Overlapping diseases and the impact of COVID-19

EP. 15: Overlapping diseases and the impact of COVID-19

EP. 16: Agents in the pipeline for dry eye disease

EP. 16: Agents in the pipeline for dry eye disease

EP. 17: Novel agents in the pipeline for dry eye disease

EP. 17: Novel agents in the pipeline for dry eye disease

EP. 1: Generic vs. Branded Ophthalmic Medications

EP. 1: Generic vs. Branded Ophthalmic Medications

EP. 2: Cost and Substitution Issues

EP. 2: Cost and Substitution Issues

EP. 3: Patient Counseling on Generic vs. Branded

EP. 3: Patient Counseling on Generic vs. Branded

EP. 4: Dry Eye Disease Epidemiology

EP. 4: Dry Eye Disease Epidemiology

EP. 5: Impact of Dry Eye on Surgical Outcome; Patient Screening

EP. 5: Impact of Dry Eye on Surgical Outcome; Patient Screening

EP. 6: Glaucoma Medications and Dry Eye Disease

EP. 6: Glaucoma Medications and Dry Eye Disease

EP. 7: Initiating Anti-Inflammatory/Immunomodulatory Therapy

EP. 7: Initiating Anti-Inflammatory/Immunomodulatory Therapy

EP. 8: Cyclosporine Formulation Challenges

EP. 8: Cyclosporine Formulation Challenges

EP. 9: Lifitegrast Experience and Patient Counseling

EP. 9: Lifitegrast Experience and Patient Counseling

EP. 10: Role of the Technician

EP. 10: Role of the Technician

EP. 11: The Technician’s Role

EP. 11: The Technician’s Role